TABLE 2.
Crude and adjusted seroprevalence estimates by age group in Ouagadougou and Bobo‐Dioulasso (Burkina Faso, March 2021).
| a: Crude and ZD‐adjusted a seroprevalence estimates for anti‐SARS‐CoV‐2 antibodies in adults (aged >18 years) | ||||
|---|---|---|---|---|
| Variables | All | SARS‐CoV‐2 seropositive N (%) | Seroprevalence (95% confidence interval) | |
| Crude | ZD‐adjusted a | |||
| Overall | 3982 | 2693 (67.6) | 67.6 (66.2–69.1) | 67.6 (65.9–69.3) |
| Sex | ||||
| Female | 2000 | 1351 (67.5) | 67.5 (65.5–69.6) | 67.5 (65.2–69.8) |
| Male | 1982 | 1342 (67.7) | 67.7 (65.6–69.8) | 67.7 (65.5–69.9) |
| Age groups | ||||
| 18–59 years old | 2556 | 1725 (67.5) | 67.5 (65.6–69.3) | 67.5 (65.5–69.4) |
| ≥60 years old | 1426 | 968 (67.9) | 67.9 (65.4–70.3) | 67.9 (65.2–70.5) |
| Age and sex | ||||
| 19–59‐year‐old men | 1279 | 867 (67.8) | 67.8 (65.2–70.3) | 67.8 (65.1–70.3) |
| 19–59‐year‐old women | 1277 | 858 (67.2) | 67.2 (64.5–69.8) | 67.2 (64.3–70.0) |
| 60 years old or over | 1426 | 968 (67.9) | 67.9 (65.4–70.3) | 67.9 (65.2–70.5) |
| City | ||||
| Bobo‐Dioulasso | 1291 | 861 (66.7) | 66.7 (64.1–69.3) | 66.7 (63.8–69.5) |
| Ouagadougou | 2691 | 1832 (68.1) | 68.1 (66.3–69.8) | 68.1 (65.9–70.2) |
| Symptoms | ||||
| Yes | 2405 | 1634 (67.9) | 67.9 (66.0–69.8) | 67.9 (66.0–69.8) |
| No | 1577 | 1059 (67.1) | 67.1 (64.8–69.5) | 67.1 (64.1–70.1) |
| b: Crude and ZD‐adjusted a seroprevalence estimates for anti‐SARS‐CoV‐2 antibodies in young participants (aged 10–18 years) | ||||
|---|---|---|---|---|
| Variables | All | SARS‐CoV‐2 seropositive N (%) | Seroprevalence (95% confidence interval) | |
| Crude | ZD‐adjusted a | |||
| Overall | 1258 | 860 (68.4) | 68.4 (65.7–70.9) | 68.4 (65.4–71.2) |
| Sex | ||||
| Female | 710 | 470 (66.2) | 66.2 (62.6–69.7) | 66.2 (62.6–69.7) |
| Male | 548 | 390 (71.2) | 71.2 (67.2–74.9) | 71.2 (66.6–75.4) |
| Age groups | ||||
| 10–14 years old | 631 | 395 (62.6) | 62.6 (58.7–66.4) | 62.6 (58.4–66.7) |
| 15–18 years old | 627 | 465 (74.2) | 74.2 (70.5–77.5) | 74.2 (70.5–77.6) |
| Age and sex | ||||
| Boys 10–14 years old | 308 | 204 (66.2) | 66.2 (60.6–71.5) | 66.2 (59.9–72.2) |
| Girls 10–14 years old | 323 | 191 (59.1) | 59.1 (53.5–64.5) | 59.1 (53.5–64.6) |
| Boys 15–18 years old | 240 | 186 (77.5) | 77.5 (71.7–82.6) | 77.5 (71.5–82.8) |
| Girls 15–18 years old | 387 | 279 (72.1) | 72.1 (67.3–76.5) | 72.1 (67.3–76.5) |
| City | ||||
| Bobo‐Dioulasso | 409 | 273 (66.7) | 66.7 (61.9–71.3) | 66.7 (61.3–71.9) |
| Ouagadougou | 849 | 587 (69.1) | 69.1 (65.9–72.2) | 69.1 (65.6–72.5) |
| Symptoms | ||||
| Yes | 365 | 246 (67.4) | 67.4 (62.3–72.2) | 67.4 (62.3–72.2) |
| No | 865 | 601 (69.5) | 69.5 (66.3–72.5) | 69.5 (65.9–72.9) |
a
The ZD‐adjusted uses standard methods to obtain point estimates of seroprevalence but with ‘robust’ standard errors that are calculated based on the observed variability in seroprevalence among clusters.